Strategic Overview

EMPE develops mfloDx, a molecular test for TB and drug resistance detection.

Innovation Portfolio

mfloDx™ MDR-TB
Category: DRUG RESIST. Stage: Commercial

Innovative diagnostic solution.

Molecular Sputum

Key Milestones

mfloDx MDR-TB drug resistance test
RIF resistance: 93% sensitivity
<3 hour turnaround
District-level capability
Commercial availability